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Beyond bevacizumab: an outlook to 
new anti-angiogenics for the 
treatment of ovarian cancer
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In addition to the monoclonal vascular endothelial growth factor (VEGF) antibody bev-
acizumab, several alternative anti-angiogenic treatment strategies for ovarian cancer 
patients have been evaluated in clinical trials. Apart from targeting extracellular receptors 
by the antibody aflibercept or the peptibody trebananib, the multikinase inhibitors pazo-
panib, nintedanib, cediranib, sunitinib, and sorafenib were developed to interfere with 
VEGF receptors and multiple additional intracellular pathways. Nintedanib and pazo-
panib significantly improved progression-free survival in two positive phase III trials for 
first-line therapy. A reliable effect on overall survival could, however, not be observed for 
any anti-angiogenic first-line therapies so far. In terms of recurrent disease, two positive 
phase III trials revealed that trebananib and cediranib are effective anti-angiogenic agents 
for this indication. Patient selection and biomarker guided prediction of response seems 
to be a central aspect for future studies. Combining anti-angiogenics with other targeted 
therapies to possibly spare chemotherapy in certain constellations represents another 
very interesting future perspective for clinical trials. This short review gives an overview 
of current clinical trials for anti-angiogenic treatment strategies beyond bevacizumab. 
In this context, possible future perspectives combining anti-angiogenics with other tar-
geted therapies and the need for specific biomarkers predicting response are elucidated.
Keywords: ovarian cancer, anti-angiogenic therapy, multikinase inhibitors, pazopanib, trebananib, cediranib, 
nintedanib
introduction
With implementation of the monoclonal vascular endothelial growth factor (VEGF) antibody beva-
cizumab to first-line treatment of ovarian cancer patients, the first targeted anti-angiogenic therapy 
for this indication has demonstrated efficacy and was approved in several countries. Following the 
results of the ICON7 and the GOG-218 study (first-line treatment) (1, 2), the OCEANS (platinum-
sensitive recurrence) (3), and the AURELIA trials (platinum-resistant recurrence) (4), bevacizumab 
is now available for many therapeutic settings in ovarian cancer. However, as efficacy could only be 
demonstrated with regard to progression-free survival (PFS) in the target groups, all studies failed 
to show a reliable effect on overall survival (OS).
Further tailored treatment strategies are still under investigation to improve efficacy and pos-
sibly reduce toxicity. Apart from an additional antibody (aflibercept) inhibiting the VEGF pathway 
further anti-angiogenic targets have been identified to compromise carcinogenesis in ovarian 
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cancer patients. With the angiopoietin cascade a parallel, VEGF-
independent signal pathway was detected as a possible target 
for the novel peptibody trebananib and investigated in clinical 
trials. In addition, several multikinase inhibitors were developed 
to interfere with the VEGF receptors and multiple intracellular 
pathways in addition to the VEGF cascade (e.g., FGF and PDGF), 
which could be implemented by the introduction of pazopanib, 
nintedanib, cediranib, sunitinib as well as sorafenib. All these 
drugs have been studied in clinical trials or are still under 
investigation. This review gives a focused overview of potential 
anti-angiogenic treatment strategies beyond bevacizumab and 
summarizes the current evidence.
inhibition of Angiogenesis via the 
Angiopoietin Pathway
Trebananib
The peptibody trebananib (AMG386) blocks the connection of 
the angiopoietins Ang1/Ang2 to the Tie2 receptor and therefore 
addresses a VEGF independent, parallel anti-angiogenic pathway. 
Following promising phase II trials (5), trebananib was investigated 
for recurrent ovarian cancer in the international, double-blind 
phase III TRINOVA-1 trial in which weekly paclitaxel 80 mg/m2 
was applied with trebananib 15 mg/kg i.v. weekly or placebo (6). In 
this trial, 919 patients with recurrent ovarian cancer, a platinum-
free interval <12 months and ≤3 prior therapies were included. 
The trebananib arm had a significantly improved median PFS of 
2.8 months [7.2 vs. 5.4 months; hazard ratio (HR) 0.66; 95% CI 
0.57–0.77; <0.001] (6). Thus, the study met the primary endpoint, 
although no improvement of OS was seen (19.3 vs. 18.3 months; 
HR 0.95; 95% CI 0.81–1.11) (7). Compared to bevacizumab, a dif-
ferent profile of adverse events (AEs) was noted. In general, treat-
ment was well tolerated with reported edema, ascites, and pleural 
effusions but less traditional VEGF-associated effects (hyperten-
sion, proteinuria, thromboembolic events). Although a planned 
study for patients with platinum-sensitive recurrent disease was 
not initiated, an additional phase III, double-blind study for first-
line treatment comparing chemotherapy of carboplatin/paclitaxel 
with trebananib in combination with chemotherapy followed by 
a subsequent weekly trebananib maintenance therapy vs. placebo 
(AGO-OVAR 18, TRINOVA-3) has completed recruitment and is 
currently under follow-up.
inhibition of Angiogenesis by Targeting 
Multiple veGF Proteins
In addition to VEGF, the target of bevacizumab, there are further 
members of the VEGF pathway that can be addressed by investi-
gational agents possibly influencing angiogenesis.
Aflibercept
Composed of VEGF binding domains from extracellular regions 
of the VEGF receptor 1 (VEGFR-1) and VEGFR-2, the fusion 
protein aflibercept has broad affinity binding VEGF-A, VEGF-B 
and also the placental growth factor (PlGF) (8). So far, this agent 
has been studied in phase II trials with relapsed ovarian cancer 
patients.
Two studies concentrated on patients with platinum-resistant 
disease and symptomatic malignant ascites with the primary 
endpoint “time to repeat paracentesis” (9, 10). Both studies could 
demonstrate a better control of malignant ascites with a reduc-
tion of the interval between paracenteses (e.g., 55.1 vs. 23.3 days, 
respectively; 95% CI 10.6–53.1; p = 0.0019) (10) although a sur-
vival benefit was not achieved. In a further phase II trial, the dose 
of either 2 or 4 mg/kg aflibercept every 2 weeks was compared in 
294 patients (11). In both arms, the assumed overall response rate 
(ORR) of >5% could not be reached (0.9 vs. 4.6%) (11). Grade 3/4 
adverse were noted with hypertension in up to 27.5%, dyspnea in 
up to 20%, and proteinuria in up to 9.4% of patients. A higher rate 
of intestinal perforation was observed although the rates differed 
significantly between the three trials with 1/16 (6.3%) (9), 3/29 
(10.3%) (10), and 3/215 patients (1.4%) (11).
As a consequence of these results with low efficacy, no phase III 
trials investigating aflibercept have been initiated to date.
inhibition of Angiogenesis by  
Multikinase inhibitors
Compared to the previous anti-angiogenic agents targeting 
the extracellular receptors, multikinase inhibitors exhibit their 
potential via intracellular blockade of different signal transduc-
tion pathways.
Pazopanib
Pazopanib is an oral tyrosine kinase inhibitor targeting three dif-
ferent protein kinases (VEGFR, PDGFR, and c-KIT). This drug 
exhibits both, anti-angiogenic as well as anti-tumorigenic, effects 
and was already proven to be effective in renal cell cancer (12). 
Following promising data in phase II trials (13, 14), a randomized, 
double-blind phase III study (AGO OVAR 16) with 940 patients was 
initiated by the Arbeitsgemeinschaft Gynaekologische Onkologie 
(AGO) for first-line treatment. This trial addressed for the first 
time a solely anti-angiogenic maintenance therapy. Pazopanib vs. 
placebo subsequent to standard chemotherapy with carboplatin 
and paclitaxel was administered orally in a dose of 800  mg. A 
significant improvement in PFS of 5.6 months for patients in the 
pazopanib arm was noted (median 17.9 vs. 12.3 months; HR 0.77; 
95% CI 0.64–0.91; p = 0.002) (15). However, no difference in OS 
was seen. A significant higher rate of grade 3 or 4 AEs, mainly 
hypertension (30.8%), neutropenia (9.9%), liver-related toxicity 
(9.4%), and diarrhea (8.2%), was reported in the pazopanib group. 
In 33% of patients in the pazopanib arm, treatment was discontin-
ued due to AEs, while this rate was only at 6% in the placebo arm. 
Currently, pazopanib is still investigated in different phase II stud-
ies (e.g., NOGGO-TOPAZ, an ongoing phase II study for patients 
with platinum-resistant recurrence: pazopanib 400 mg/day orally 
vs. placebo in combination with topotecan 4 mg/m2 weekly).
nintenanib
Based on significant benefit for lung cancer treatment and 
promising results from a phase II study in relapsed ovarian 
cancer (16, 17), another oral triple angiokinase inhibitor nint-
edanib (BIBF 1120) targeting VEGFR, PDGFR, and FGFR was 
studied for first-line therapy of ovarian cancer patients. In the 
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positive prospective, randomized phase III study (AGO-OVAR 
12/LUME-Ovar 1) nintedanib 200 mg BID vs. placebo was taken 
parallel to chemotherapy with carboplatin AUC 5/6 and pacli-
taxel 175 mg/m2 followed by a maintenance phase for a maximum 
duration of 120 weeks (18). In a total of 1366 included patients, 
median PFS, the primary endpoint, was prolonged from 16.6 to 
17.3 months (HR 0.84; 95% CI 0.72–0.98; p = 0.024). Of note, 
treatment-related toxicity was significantly increased in the nint-
edanib arm with predominantly hematologic and gastrointestinal 
AEs (Grad ≥3 22 vs. 2%) (18). So far, no significant effect on 
OS was noted. Although approval of this multikinase inhibitor is 
currently not expected, these results add important information 
to future studies in which patient selection and optimized toler-
ability will represent important aspects of the study design.
Cediranib
The oral tyrosine kinase inhibitor cediranib is a potent inhibitor 
of all three VEGF receptors (VEGFR-1, -2, -3) and c-kit with 
pronounced selectivity for VEGFR-2. It demonstrated activity 
in an open-label phase II trial among 46 patients with recurrent 
disease although the dose of cediranib had to be reduced from 
45 to 30 mg/day due to significant toxicity, such as hypertension, 
fatigue, and diarrhea (19). Based on these results, the randomized, 
double-blind, placebo-controlled phase III trial ICON6 was initi-
ated to evaluate cediranib in 456 patients with platinum-sensitive 
recurrent disease (20). Patients were randomized to receive six 
cycles of carboplatin AUC5 or 6 plus paclitaxel 175 mg/m2 with 
either placebo, cediranib 20 mg/day, followed by placebo (con-
current), or cediranib 20 mg/day, followed by cediranib (concur-
rent plus maintenance) (20). In this further reduced dosage, the 
treatment was sufficiently well tolerated during initial toxicity 
assessment (20).
The first presentation of results demonstrated significantly 
improved PFS in the cediranib concurrent and maintenance arm 
compared to placebo (11.4 vs. 9.4 months; HR 0.68; p = 0.002) as 
well as significantly improved median OS (20.3 vs. 17.6 months; 
HR 0.70; p = 0.042) (21). The most common cediranib-related 
AEs included diarrhea, nausea, and fatigue. Although final publi-
cation of results is still pending, ICON6 seems to be the first trial 
with targeted therapies exhibiting a significant effect on OS in an 
unselected patient cohort (21).
Cediranib raised further attention following the presentation 
of a randomized phase II trial investigating the combination of 
cediranib 30  mg daily and the poly(ADP-ribose) polymerase 
(PARP) inhibitor olaparib 200 mg BID vs. olaparib 400 mg BID 
alone in 90 women with recurrent platinum-sensitive ovarian 
cancer and a deleterious germline BRCA1 or 2 mutation. The 
chemotherapy-free experimental arm of cediranib and olaparib 
significantly improved PFS from 9.0 to 17.7 months (HR 0.42; 95% 
CI 0.23–0.76; p = 0.005), while OS data are not mature yet (22). 
As drug-related AEs were more common in the cediranib plus 
olaparib arm (70% of patients with grade 3 or higher event) than 
in olaparib monotherapy (11%) further envisaged phase III trials 
need to account for tolerabilty of this novel combination (22). In 
this context, the international randomized phase III PAOLA-1 
trial was recently initiated by the French Groupe d’Investigateurs 
Nationaux pour l’Étude des Cancers Ovariens (GINECO) to 
investigate the combination of chemotherapy, anti-angiogenic 
therapy and PARP inhibitors in the first-line setting for ovarian 
cancer patients. Accounting for the approval status in Europe, 
bevacizumab instead of cediranib was chosen for combination 
with olaparib and platinum-based chemotherapy.
Sunitinib
A further multikinase inhibitor targeting VEGF receptors, PDGF 
receptors, stem cell factor receptor (KIT) and FMS-like tyrosine 
kinase-3 (FTL3), has also been included in phase II studies for 
ovarian cancer and recurrent disease (23). Initially, sunitinib as 
single agent was investigated at a dose of 50 mg daily over 4 weeks 
of a 6-week cycle, which was adopted to continuous 37.5 mg daily 
dosing in the second stage of accrual due to higher incidence of 
ascites or pleural effusions during off-treatment intervals (24). 
Although sunitinib exhibited modest activity in recurrent plati-
num-sensitive ovarian cancer, a dosage-dependent response was 
noted favoring the 50 mg intermittent schedule (24). Common 
AEs included fatigue, gastrointestinal symptoms, hand-foot 
syndrome, and hypertension. No gastrointestinal perforation 
occurred during treatment period (24).
The phase II AGO 2.11 study investigated single-agent 
sunitinib in 73 patients with platinum-resistant ovarian cancer 
in which moderate activity was noted. Included patients had 
received ≤3 prior chemotherapy regimens and were allocated 
to two treatment arms (arm 1: non-continuous treatment with 
50 mg sunitinib daily orally for 28 days followed by 14 days off 
drug; arm 2: continuous treatment with 37.5 mg sunitinib admin-
istered daily). In this trial, patients receiving non-continuous 
treatment responded better to the systemic therapy regarding 
PFS [arm 1: 4.8 (2.9–8.1) months; arm 2: 2.9 (2.9–5.1) months], 
while the median OS [arm 1: 13.6 (7.0–23.2) months; arm 2: 13.7 
(8.4–25.6) months] as well as the pattern of AEs did not differ 
significantly (25). So far, no phase III trial has been initiated.
Sorafenib
As well as the previous molecules, sorafenib is an oral multitar-
geted tyrosine kinase inhibitor blocking VEGFR2, VEGFR3, as 
well as PDGFR beta, Flt-3, and c-kit (26). In addition to these 
targets, sorafenib has partial inhibitory effects on portions of the 
RAS/RAF/MEK/ERK signaling pathway, which is known to play 
a central role in ovarian cancer development, especially in low-
grade tumors (26).
In a phase II study of 71 patients concentrating on recurrent 
ovarian cancer, a modest anti-tumor effect could be demonstrated 
for sorafenib maintenance treatment at dose of 400 mg twice a 
day following chemotherapy. However, this impact was achieved 
at the expense of significant toxicity (27). Comparable results 
were revealed by a randomized phase II trial of 246 patients with 
complete remission after first-line chemotherapy in which no 
significant difference between treatment with sorafenib 400 mg 
twice a day vs. placebo could be demonstrated for PFS (median 
12.7 vs. 15.7  months; HR 1.09; 95% CI 0.72–1.63) (28). Of 
note, high rates of dose reductions (67.5 vs. 30.1%) and early 
discontinuations were noted in the sorafenib arm, interfering 
with the efficacy analysis. The most common ≥grade 3 AEs were 
hand-foot skin reaction (39.0 vs. 0.8%) and rash (14.6 vs. 0%). 
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The authors concluded that sorafenib, therefore, should not 
be recommended as maintenance therapy for patients with 
OC experiencing complete remission (28). Other studies had 
to be prematurely closed due to low accrual of patients (29). 
Nevertheless, there are still results of clinical phase II trials for 
recurrent ovarian cancer pending in which a combination to 
mono-chemotherapy (e.g., sorafenib plus topotecan, NOGGO-
TRIAS) or a chemotherapy-free combination with bevacizumab 
is being tested.
Conclusion
Over the past years, different promising therapeutic approaches 
for anti-angiogenic therapy beyond bevacizumab have been 
investigated (Table 1). So far, four of these anti-angiogenics (tre-
bananib, pazopanib, nintedanib, and cediranib) were evaluated in 
phase III clinical trials (Table 2). While pazopanib and nintedanib 
could already demonstrate to significantly improve PFS of ovar-
ian cancer patients within first-line therapy of two positive trials, 
TABLe 1 | Overview of phase ii studies with anti-angiogenic agents for recurrent disease.
Author investigated 
agent
Study design n (rel.) Results PFS median Other end points
Trebananib
Karlan  
et al. (5)
Trebananib 10 mg/kg + paclitaxel 80 mg/m2 
q1w vs. trebananib 3 mg/kg + paclitaxel 80 mg/
m2 q1w vs. placebo + paclitaxel 80 mg/m2 q1w
161  
(1:1:1)
7.2 months (95% CI 5.3–8.1) vs. 
5.7 months (95% CI 4.6–8.0) vs. 
4.6 months (95% CI 1.9–6.7)
Overall response rate (ORR): 37 vs. 
19 vs. 27%
Aflibercept
Colombo  
et al. (9)
Aflibercept 4 mg/kg q2w (single-arm) 16 59.5 days (95% CI 41.0–83.0) Median time to repeat paracentesis: 
76.0 (95% CI 64.0–178.0) days vs. 
baseline interval (16.8 days)
Gotlieb  
et al. (10)
Aflibercept 4 mg/kg q2w vs. placebo 55  
(1:1)
6.3 weeks (95% CI 5.9–10.9) vs. 
7.3 weeks (95% CI 6.3–14.0)
Mean time to repeat paracentesis: 
55.1 (SE 7.3) vs. 23.3 (7.7) days; 
difference 31.8 days (95% CI 
10.6–53.1; p = 0.0019)
Tew et al. (11) Aflibercept 2 mg/kg q2w vs. aflibercept  
2 mg/kg q2w
294  
(1:1)
– Overall response rate (ORR): 0.9 
vs. 4.6%
Pazopanib
Friedlander  
et al. (14)
Pazopanib 800 mg daily following complete 
CA-125 response to initial platinum-based 
chemotherapy and subsequent rise
36 – Overall response rate (ORR): 18% 
in patients with measurable disease 
at baseline
Pignata  
et al. (13)
Paclitaxel 80 mg/m2 + pazopanib 800 mg daily 
vs. paclitaxel 80 mg/m2
74  
(1:1)
Median 6.35 months (95% CI 
5.36–11.02) vs. 3.49 months  
(95% CI 2.01–5.66); HR 0.42  
(95% CI 0.25–0.69); p = 0.0002
–
nintedanib
Ledermann  
et al. (16)
Nintedanib 250 mg BID vs. placebo BID 
continuously for 36 weeks as maintenance
83  
(1:1)
Thirty-six-week PFS rates: 16.3  
and 5.0%; HR 0.65 (95% CI 
0.42–1.02; p = 0.06)
–
Cediranib
Matulonis et al. (19) Cediranib 45 mg daily, subsequently 30 mg daily 
(single-arm)
47 – Overall response rate (ORR): 17% 
(95% CI 7.6–30.8%)
Liu et al. (22) Cediranib 30 mg daily + olaparib 200 mg BID vs. 
olaparib 400 mg BID alone
90  
(1:1)
17.7 vs. 9.0 months; HR 0.42  
(95% CI 0.23–0.76; p = 0.005)
–
Sunitinib
Biagi  
et al. (24)
Sunitinib 50 mg daily (4 of 6 weeks) 
subsequently continuous 37.5 mg daily dosing
30 4.1 months Overall response rate (ORR): 13.3%
Baumann et al. (25) Sunitinib 50 mg daily (4 of 6 weeks) vs. 
continuous 37.5 mg daily dosing
73 4.8 months (2.9–8.1) vs.  
2.9 months (2.9–5.1)
Overall response rate (ORR): 16.7 
vs. 5.4%
Sorafenib
Matei  
et al. (27)
Sorafenib 400 mg orally BID 71 Patients with at least 6 months  
PFS: 24% (90% CI 15–35%)
Overall response rate (ORR): 3.4%
Herzog et al. (28)  
(first-line treatment)
Sorafenib 400 mg BID vs. placebo maintenance 
in patients with complete remission after first-line 
chemotherapy
246 Median 12.7 vs. 15.7 months;  
HR 1.09 (95% CI 0.72–1.63)
–
Key characteristics and results of published phase II studies for anti-angiogenics beyond bevacizumab in case of recurrent disease.
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17.3 vs. 16.6 months; 
HR 0.84 (95% CI 
0.72–0.98; p = 0.024)
Immature data Oral anti-angiogenic therapy 
parallel to chemotherapy with 
subsequent maintenance phase
Recurrent disease
ICON6a 
[Ledermann et al. 
(21))
Cediranib 20 mg orally daily during platinum-
based chemotherapy and followed up to 
18 months vs. cediranib 20 mg orally daily 
during platinum-based chemotherapy and 
followed by placebo up to 18 months vs. 
placebo with platinum-based chemotherapy 
456  
(3:3:2)
11.4 vs. 9.4 months; 
HR 0.68; p = 0.0022
20.3 vs. 
17.6 months; HR 
0.70; p = 0.042
Platinum-sensitive recurrent 
ovarian cancer; first study with 
targeted therapy and effect on 
OS
TRINOVA-1 [Monk 
et al. (6)]
Paclitaxel 80 mg/m2 q1w + trebananib 
15 mg/kg q1w vs. paclitaxel 80 mg/m2 
q1w + placebo q1w
919  
(1:1)
7.2 vs. 5.4 months; 
HR 0.66 (95% CI 
0.57–0.77; p < 0.001)
19.3 vs. 
18.3 months; 
HR 0.95 (95% CI 
0.81–1.11; p = 0.52)
Recurrent ovarian cancer with 
<12 months platinum-free interval
Key characteristics and results of published phase III studies for anti-angiogenics beyond bevacizumab (first-line vs. recurrence).
aSo far only presentation at conference, full paper is pending.
Statistically significant p values are printed in bold.
the results of a third first-line study investigating trebananib are 
pending. However, an OS effect could not be observed for anti-
angiogenic first-line therapies so far. For recurrent disease, two 
positive phase III trials investigating trebananib and cediranib 
gave new insights to find additional, effective anti-angiogenic 
agents for this group of patients.
Emerging data suggests that patient selection might represent 
a central aspect for future studies. Specific histological subtypes 
and patients mostly benefiting from a distinct treatment regimen 
need to be identified to avoid unnecessary toxicity and dete-
rioration of quality of life of non-responding patients. Especially 
regarding maintenance therapies, patient-reported outcomes to 
assess quality of life more thoroughly as well as interpretation of 
significant AEs will become progressively relevant.
Combining anti-angiogenics with other targeted therapies 
to possibly spare chemotherapy in certain constellations, as 
shown for cediranib and olaparib in BRCA-mutated patients, 
represents another very interesting future perspective for clinical 
trials. Identifying drugs with a well-tolerated dosage and dosing 
schedule, optimal combination partners, and a selection process 
for patients with expected high response rates will be the major 
aims for future investigations in ovarian cancer.
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